Russo Partners LLC is an American public and investor relations firm based in New York City, New York.
Organization
| Name | Position | Notes |
|---|---|---|
| Tony Russo | Chairman and Chief Executive Officer[1] | Noonan/Russo |
| David Schull | President | - |
| Brad Prunty | Executive Vice President | - |
Partners
Strategic partners of Russo Partners include:[2]
- Clearpath Health Communications
- M Booth Health
- Rob Strickland
- Solomon Wilcots
- VOZ Advisors
Clients
Russo Partners' clients include:[3]
- Alder BioPharmaceuticals
- Athersys[4]
- Axovant Sciences
- Gaumard Scientific
- Sutro Biopharma
- United Biomedical-Asia (UBI-Asia)[5]
- Vaxxinity[6]
- Vericel
External links
Leadership. Russo Partners LLC. Retrieved November 19, 2024, from http://archive.today/2024.11.19-011731/https://russopartnersllc.com/the-agency/leadership/ ↩︎
Strategic Partners. Russo Partners LLC. Retrieved November 19, 2024, from https://russopartnersllc.com/the-agency/strategic-partners/ ↩︎
Work & Results. Russo Partners LLC. Retrieved November 19, 2024, from https://russopartnersllc.com/work-results/ ↩︎
Work & Results. Russo Partners LLC. Retrieved December 18, 2019, from https://web.archive.org/web/20191218073520/https://russopartnersllc.com/work-results/ ↩︎
Schull, D., & Stabinski, M. (2022, April 6). United Biomedical-Asia (UBI-Asia) Announces Phase 1/2 and Phase 1 Extension Trial Results of Multitope SARS-CoV-2 Vaccine Published in the Journal of Clinical Investigation. PR Newswire; United Biomedical, Inc.-Asia. https://web.archive.org/web/20230325211400/https://www.prnewswire.com/news-releases/united-biomedical-asia-ubi-asia-announces-phase-12-and-phase-1-extension-trial-results-of-multitope-sars-cov-2-vaccine-published-in-the-journal-of-clinical-investigation-301518318.html ↩︎
Building a Social Media Program from the Ground Up. Russo Partners LLC. Retrieved April 6, 2023, from https://web.archive.org/web/20230406051132/https://russopartnersllc.com/case_study/building-a-social-media-program-from-the-ground-up/ ↩︎
